v3.26.3
GENERAL AND GOING CONCERN (Details Narrative)
12 Months Ended
Feb. 18, 2026
USD ($)
shares
Jul. 31, 2026
USD ($)
Segment
Jul. 31, 2025
USD ($)
Accumulated deficit   $ 146,659,826 $ 111,755,564
Cash flows from operating activities   28,651,323 $ 28,170,520
Gross proceeds from equity   $ 34,709,566  
Goodwill, Reporting Unit, Number | Segment   1  
Common Stock [Member]      
Number of shares issued | shares 23,972,589    
Briacell Therapeutics [Member]      
Fund for research and development $ 3,000,000    
BriaPro Therapeutics Corp, [Member]      
Ownership percentage 78.00%   78.00%